Chiesi Farmaceutici S.p.a.

Universita′ Degli Studi Di Milano

Micol Cirilli

Marisa Pertile

Andrea Gazzaniga

Matteo Cerea

The disclosure is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular, the disclosure is also directed to modified release tablets suitable either for twice daily administration or once daily administration. The disclosure is also directed to methods of making and using the same.

Modified release pharmaceutical formulations comprising deferiprone

The disclosure is directed to pharmaceutical compositions for oral administration in form of coated tablets that exhibit modified release properties when administered as either whole or half tablets. In particular, the disclosure is directed to modified release tablets comprising deferiprone, said tablets being suitable for twice daily oral administration. The disclosure is also directed to methods of making and using the same.

Growing community of inventors

Milan, Italy

Micol Cirilli